Strategic funder Curie.Bio is a $1B venture-capital firm specializing in seed and Series A rounds for biotech and therapeutics, offering potential engagement as a lead investor or co-investor to accelerate portfolio companies.

Portfolio leverage With a track record contributing to over 40 FDA-approved drugs and a hands-on, founder-focused approach, Curie.Bio can be tapped to accelerate clinical milestones, provide strategic partnerships, and facilitate introductions to regulatory and industry networks.

Recent expansion The firm recently announced a significant financing round and has demonstrated expansion into new venture models (such as supporting spinouts and collaborations like ForwardTx), signaling openness to new therapeutic ventures and collaboration structures.

Industry reach Operating remotely in the US with a sizable team, Curie.Bio engages across biotech, therapeutics, and possibly environmental/industrial biotech initiatives (evidenced by Nutri Clean for water treatment), suggesting opportunities in diversified life-science domains.

Engagement opportunities Given leadership moves (CSO hire) and ongoing partnerships, there is potential for senior-brokered co-development, advisory roles, and structured funding programs tailored to early-stage companies seeking capital-efficient paths to milestones.